诺华地拉罗司进入医保了吗？

It was developed by Novartis and the first oral iron chelator approved by the FDA for routine use in 2005. The FDA granted deferasirox orphan drug status for the treatment of iron overload in non-transfusion-dependent thalassemia. It is currently on the market in more than 80 countries.

In 2010, Novartis deferasirox was approved for marketing in China and is approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above and chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

Novartis was founded in 1996 from the merger of two Basel-based chemical and pharmaceutical companies, Ciba-Geigy and Sandoz.

So is Novartis deferasirox included in medical insurance?

It is understood that deferasirox has been included in medical insurance, and patients can use medical insurance for reimbursement.

Although the price of deferasirox under medical insurance has been reduced a lot, it still puts a lot of financial pressure on patients without medical insurance and ordinary patients. Therefore, most domestic patients use the version marketed abroad!

According to Medical Companion Travel, the price of Novartis abroad is relatively close to the people. The specification is 400mg*30 tablets/box and the price is around 400$. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for the specific price!

Recommended related hot articles: /newsDetail/97201.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.